AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 3(4), 1954, pp. 714-727
Copyright © 1954 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedheim, E. A. H.
Right arrow Articles by Martins, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedheim, E. A. H.
Right arrow Articles by Martins, A. V.

Treatment of Schistosomiasis Mansoni with Antimony-a, a'-Dimercapto-Potassium Succinate (TWSb)

Ernst A. H. Friedheim, José R. da Silva AND Amilcar V. Martins
Laboratory of Ernst A. H. Friedheim, New York City1; Hospital dos Servidores do Eslado, Rio de Janeiro; and the Medical School of the University of Belo Horizonte, Brazil.

TWSb is a water soluble trivalent organic antimonial of a new type, 50 times less toxic than tartar emetic (mouse), applicable by intramuscular and intravenous injection. In laboratory animals TWSb is therapeutically active in Trypanosoma congolense and T. brucei trypanosomiasis, in Litmosoides carinii filariasis and in Manson's schistosomiasis.

Seventy clinical cases of active schistosomiasis mansoni have been treated with various intensive intravenous and semi-intensive intramuscular dosage schedules. A one-to-three-day intensive treatment with TWSb has an immediate blocking effect on egg deposition. Immature eggs, numerous before treatment, were conspicuously absent in all of 35 cases submitted to rectal biopsy 2 to 21 days after treatment.

In 58 clinical cases of active schistosomiasis mansoni, TWSb permitted a safe 1-to-3-day intensive intravenous treatment with doses totaling 1.1 to 2.3 grams, resulting in 53 (91 per cent) presumptive cures, controlled up to 12 months after the treatment by rectal biopsy and feces examination. Five (9 per cent) of these 58 cases relapsed during the second to sixth post-treatment month. These 5 therapeutic failures received treatment with doses well within the tolerated range, i.e., with doses which can be safely increased.

Side effects of the intensive treatment were limited to alimentary vomiting, transitory benign skin rashes and rheumatoid pains toward the end of the treatment.

The detoxification of antimony realized in TWSb is particularly evident in electrocardiogram and blood pressure studies demonstrating that even massive doses have no significant cardiovascular effect. The following points suggest TWSb as a medication suited for the public health treatment of schistosomiasis:

  1. the rapid treatment within 2 days;
  2. the rapid blocking of egg deposition, probably within the first two post-treatment days;
  3. the safety of the treatment;
  4. the high presumptive cure rate of better than 90 per cent.


1 333 West 52nd Street, New York 19, N. Y.




This article has been cited by other articles:


Home page
Hum Exp ToxicolHome page
O Torres-Alanis, L Garza-Ocanas, and A Pineyro-Lopez
Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men
Human and Experimental Toxicology, November 1, 2002; 21(11): 573 - 577.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1954 by the American Society of Tropical Medicine and Hygiene.